收藏切换
Rapid health technology assessment of trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer
收藏切换
PDF
Zhi-qi ZHANG, Zhuo ZHANG, Qian-xin LIU, Xiao-cong PANG, Ying ZHOU
Chinese Journal of Clinical Pharmacology | 2025, 41(6) : 872 - 876
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(6): 872-876
Reader’s Field
Rapid health technology assessment of trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer
Full
Zhi-qi ZHANG, Zhuo ZHANG, Qian-xin LIU, Xiao-cong PANG, Ying ZHOU
Affiliations
  • Department of Pharmacy, Peking University First Hospital, Beijing 100034, China
Published: 2025-03-28 doi: 10.13699/j.cnki.1001-6821.2025.06.023
Outline
收藏切换
Objective

To evaluate the efficacy, safety, and economy of trastuzumab emtansine (T-DM1) in the treatment of human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer based on the rapid health technology assessment methodology, and to provide a reference for the rational use of the drug in the clinic.

Methods

A systematic search of Chinese and English databases such as PubMed, Embase, the Cochrane Library, CNKI, Wanfang, SinoMed, etc. was performed to screen the literature according to the inclusion and exclusion criteria, extract the data, evaluate the quality of the literature, and qualitatively analyze the results.

Results

T-DM1 had comparable or even superior efficacy in terms of progression-free survival (PFS) and overall survival (OS) compared with conventional anti-HER2 treatment regimens as well as other chemotherapeutic regimens. Some regimens, such as docetaxel+trastuzumab+patuximab, and pyrrolitinib+capecitabine, might be superior to T-DM1 in terms of PFS and OS. Adverse effects of T-DM1 were mainly liver function abnormalities and thrombocytopenia, and overall the safety profile was better, with a lower probability of serious adverse effects. In terms of economy, T-DM1 was more favorable than T-Dxd, and further evaluation was still needed compared with other regimens.

Conclusion

T-DM1 has favorable efficacy and safety, with economics to be further evaluated.

trastuzumab emtansine  /  advanced breast cancer  /  health technology assessment
Zhi-qi ZHANG, Zhuo ZHANG, Qian-xin LIU, Xiao-cong PANG, Ying ZHOU. Rapid health technology assessment of trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (6) : 872 -876 . DOI: 10.13699/j.cnki.1001-6821.2025.06.023
Year 2025 volume 41 Issue 6
PDF
1
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.06.023
  • Receive Date:2024-10-10
  • Online Date:2026-08-04
  • Published:2025-03-28
Article Data
Affiliations
History
  • Received:2024-10-10
Funding
Affiliations
    Department of Pharmacy, Peking University First Hospital, Beijing 100034, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.06.023
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT